CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Senior Leerink analyst downgrades Bristol Myers, citing pipeline fears

Negative
AI Analysis

Summary

A Leerink analyst downgraded Bristol Myers Squibb from outperform due to skepticism about upcoming pipeline catalysts. The analyst cited concerns about key upcoming developmental milestones for the company.

Importance:4/10
Sentiment:
-0.70
downgradepipeline riskanalyst notecatalyst concerns
Related Companies

Read the original article

Published by Endpoints News on October 5, 2026 7:40 PM

Read Original